financetom
Business
financetom
/
Business
/
Databricks competitor Chalk raises $50 million series A
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Databricks competitor Chalk raises $50 million series A
May 28, 2025 6:24 AM

SAN FRANCISCO, May 28 (Reuters) - Artificial

intelligence infrastructure startup Chalk said Wednesday it had

raised a $50 million Series A funding round, valuing the company

at $500 million. Felicis led the round.

San Francisco-based Chalk helps enterprises get their

proprietary data into AI and machine learning models quickly,

enabling companies to use AI to make up-to-date decisions. The

company says fintech firms like MoneyLion use Chalk to enable

instant decision-making for fraud detection and loan approvals,

while solar company Sunrun ( RUN ) uses Chalk to figure out

where to put solar panels on a roof.

"The old school model would be for a company to process data

in a batch process, but increasingly, companies want to make

decisions in real-time," said Chalk CEO Marc Freed-Finnegan. The

company is co-founded by Elliot Marx and Andy Moreland.

Freed-Finnegan said Chalk competes with Databricks and

Snowflake, data analytics platforms that help

enterprises build and govern data and AI applications, but Chalk

differentiates itself by enabling real-time data processing for

AI.

Such companies have benefited from the AI boom by selling

more tools that help clients build and deploy AI applications

using the growing volume of data they already store with the

company. Late last year, Databricks secured a record-breaking

$10 billion in funding, one of the largest VC funding rounds in

history.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Gilead's liver disease drug
US FDA approves Gilead's liver disease drug
Aug 14, 2024
Aug 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' ( GILD ) drug for a chronic and potentially fatal liver disease that mostly affects women. The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them. It mainly affects women aged...
Market Chatter: Johnson & Johnson to Announce Majority Support for $6.48 Billion Talc Settlement
Market Chatter: Johnson & Johnson to Announce Majority Support for $6.48 Billion Talc Settlement
Aug 14, 2024
01:20 PM EDT, 08/14/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) is set to announce wider support for a $6.48 billion settlement to resolve tens of thousands of lawsuits claiming its talc products, including Baby Powder, caused cancer, Reuters reported Wednesday, citing people familiar with the matter. The company intends to disclose that more than 75% of claimants...
Equinor, Dominion are winners in US Central Atlantic offshore wind auction
Equinor, Dominion are winners in US Central Atlantic offshore wind auction
Aug 14, 2024
Aug 14 (Reuters) - A U.S. government sale of offshore wind development rights for two areas off the coasts of Delaware, Maryland and Virginia yielded nearly $93 million in winning bids, the Interior Department said on Wednesday. The winning bidders were Norway's Equinor ( EQNR ) and Virginia Electric and Power Co, a division of U.S. utility Dominion. ...
DaVita Closes $1 Billion Private Senior Notes Offering
DaVita Closes $1 Billion Private Senior Notes Offering
Aug 14, 2024
01:03 PM EDT, 08/14/2024 (MT Newswires) -- DaVita ( DVA ) said in a regulatory filing Wednesday that it completed a private offering Tuesday of approximately $1 billion of its 6.875% senior notes due 2032. The healthcare company said it also agreed to establish an incremental tranche of senior secured term A loans worth about $1.1 billion. The loans mature...
Copyright 2023-2026 - www.financetom.com All Rights Reserved